ArticleScientific reports2017
Carbon Adsorbents With Dual Porosity for Efficient Removal of Uremic Toxins and Cytokines from Human Plasma.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Trial
- Functional Nanostructured Carbon Honeycomb Monoliths for Hemoadsorption: Preliminary Studies on Biocompatibility, Protein-Bound Uremic Toxins and Inflammatory Cytokines Elimination.International journal of molecular sciences · 2026Article
- Functional Carbon-Based Materials for Blood Purification: Recent Advances Toward Improved Treatment of Renal Failure and Patient Quality of Life.Bioengineering (Basel, Switzerland) · 2025Review
- Displacing the Burden: A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease.Journal of clinical medicine · 2024Review
- Hemocompatibility of β-Cyclodextrin-Modified (Methacryloyloxy)ethyl Phosphorylcholine Coated Magnetic Nanoparticles.Biomolecules · 2023Article
- Hierarchically structural layered double oxides with stretchable nanopores for highly effective removal of protein-bound uremic toxins.Separation and purification technology · 2022Article
- Research progress on the relationship between IS and kidney disease and its complications.International urology and nephrology · 2022Review
- Review
- Mixed Matrix Membranes Adsorbers (MMMAs) for the Removal of Uremic Toxins from Dialysate.Membranes · 2022Article
- Nanodiamond as a Cytokine Sponge in Infectious Diseases.Frontiers in bioengineering and biotechnology · 2022Article
- Classification of Uremic Toxins and Their Role in Kidney Failure.Clinical journal of the American Society of Nephrology : CJASN · 2021Review
- In Search of Effective UiO-66 Metal-Organic Frameworks for Artificial Kidney Application.ACS applied materials & interfaces · 2021Article
- Sponge-like Chitosan Based Porous Monolith for Uraemic Toxins Sorption.Nanomaterials (Basel, Switzerland) · 2021Article
- Article
- Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives.Toxins · 2021Review
- Innovations in approaches to remove uraemic toxins.Nature reviews. Nephrology · 2020Article
- Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.British journal of pharmacology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of patients with chronic kidney disease increases while the number of available donor organs stays at approximately the same level. Unavoidable accumulation of the uremic toxins and cytokines for these patients comes as the result of malfunctioning kidneys and their high levels in the blood result in high morbidity and mortality. Unfortunately, the existing methods, like hemodialysis and hemofiltration, provide only partial removal of uremic toxins and/or cytokines from patients' blood. Consequently, there is an increasing need for the development of the extracorporeal treatments which will enable removal of broad spectrum of uremic toxins that are usually removed by healthy kidneys. Therefore, in this work we developed and tested ordered mesoporous carbons as new sorbents with dual porosity (micro/meso) that provide selective and efficient removal of a broad range of uremic toxins from human plasma. The new sorbents, CMK-3 are developed by nanocasting methods and have two distinct pore domains, i.e. micropores and mesopores, therefore show high adsorption capacity towards small water soluble toxins (creatinine), protein-bound molecules (indoxyl sulfate and hippuric acid), middle molecules (β-2-microglobulin) and cytokines of different size (IL-6 and IL-8). Our results show that small amounts of CMK-3 could provide selective and complete blood purification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.